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Abstract 
We study the osteoinductive effect of the hyaluronic acid (HA) by using an esterified 
low-molecular HA preparation (EHA) as a coadjuvant in the grafting processes to produce 
bone-like tissue in the presence of employing autologous bone obtained from intra-oral sites, 
to treat infra-bone defects without covering membrane. 
We report on 9 patients with periodontal defects treated by EHA and autologous grafting (4 
males and 5 females, all non smokers, with a mean age of 43,8 years for females, 40,0 years 
for males and 42 years for all the group, in good health) with a mean depth of 8.3 mm of the 
infra-bone defects, as revealed by intra-operative probes. Data were obtained at baseline 
before treatment and after 10 days, and subsequently at 6,9, and 24 months after treatment. 
Clinical results showed a mean gain hi clinical attachment (gCAL) of 2.6mm of the treated sites, con-
firmed by radiographic evaluation. Such results suggest that autologous bone combined with EHA 
seems to have good capabilities in accelerating new bone formation in the infra-bone defects. 
Key words: Guided tissue regeneration, bone graft, Hyaluronic acid, biomaterials. 
INTRODUCTION 
Hyaluronic acid (HA) is a natural occurring lin-
ear polysaccharide of the extracellular matrix of con-
nective tissue, synovial ﬂuid, and other tissues. HA 
structure consists of polyanionic disaccharide units of 
glucouronic acid and N-acetyl-glucosamine con-
nected by alternating β 1–3 and β1–4 bonds [1]. There 
is no anti-genic speciﬁcity for species or tissues; and 
thus, these agents have a low potential for allergic or 
immunogenic reaction [2]. 
It is detectable in all vertebrate animals and as a 
“bioﬁlm” around bacteria [3]. HA have speciﬁc 
physical and biochemical properties in normal tissue 
that make them ideal structural compounds [1]. In 
humans, thanks to its viscoelastic properties, HA is 
the ground substance of the synovial fluid, as well as 
the skin, different organs and tissues [4,5]. 
When HA is incorporated into aqueous solution, 
hydrogen bonding occurs between adjacent carboxyl 
and N-acetyl groups; this feature allows HA to 
maintain conformational stiffness and to retain water. 
One gram of HA can bind up to 6 L of water [6]. As a 
physical background material, it has functions in 
space ﬁlling, lubrication, shock absorption, and pro-
tein exclusion. Its biochemical properties include 
modulation of inﬂammatory cells, interaction with 
the proteoglycans of the extracellular matrix and 
scavenging of free radicals [4,5].  
However, recent data indicated a certain role 
played by undersulfated glycosaminoglycans, such 
as HA, on hydroxyapatite crystal formation [7]. 
Moreover, low molecular weight HA has shown os-
teogenic properties when tested in vitro with bone 
cells, both through the intramembranous and the 
endochondral paths of osteogenesis, with the as-Int. J. Med. Sci. 2009, 6 
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sumption that HA provide differentiation of stem or 
progenitor cells before attaching to a surface (36a and 
36b) [8,9]. The application of exogenous HA and 
HA-based biomaterials showed good results in ma-
nipulating and accelerating the wound healing proc-
ess in a large number of medical disciplines, as evi-
dent in ophthalmology, dermatology, dentistry and 
rheumatology [10,11]. 
Based up on these data the aim of this study was 
to observe the potential of Esterified Hyaluronic Acid 
(EHA) as a coadjuvant of grafting processes to pro-
duce bone-like tissue in the presence of employing 
autologous bone obtained from  intra-oral sites, in 
order to treat infra-bone defects without the aid of 
membrane, confronting data obtained with previous 
reported cases used as control. 
 
PATIENTS AND METHODS 
Study drug 
Hyaloss® matrix, trade names of products 
composed entirely of an ester of hyaluronic acid with 
benzyl alcohol (HYAFF™) [2], a concentration rang-
ing of from 20 to 60 mg/ml. 
Surgical group  
We report on 9 patients with periodontal defects 
treated by EHA and autologous grafting, 4 males and 
5 females, all non smokers, with a mean age of 43,8 
years for females, 40,0 years for males and 42 years for 
all the group, in good health and with a mean depth 
of the infra-bone defects of 8.3 mm, as revealed by 
intra-operative probes.  
The Exclusion criteria included: smokers of more 
than 10 cigarettes/day, pregnant or in lactation 
women, severe systemic disease, plaque and bleeding 
indexes > 25%, infra-bone defects < 3mm, sites with 
stabilized teeth (no M2, M3), treatment with drugs 
that could interfere with the tissue regeneration 
processes, and patients failing to observe the recom-
mended oral hygiene measures. All patients under-
went non surgical periodontal treatment to reduce the 
FMPS (full mouth plaque surfaces); and FMBS (full 
mouth plaque surfaces) indexes. 
Radiographic Examination 
Pre-operative periapical radiography with a 
Rinn Centering was performed [fig. 1]. 
The examination technique was standardized to 
obtain radiographs as similar as possible. Impressions 
were made at the first examination and saved for fol-
low-up control examinations. Radiographs were per-
formed immediately before treatment and at 10 days, 
and 6, 9, and 24 months after treatment. 
Clinical Measurements 
To assess the treatment results, the following 
pre-operative and intra-operative clinical parameters 
were analyzed: 
•  FMPS; 
•  FMBS; 
•  PPD (periodontal pocket depth) [fig. 2]; 
•  R: gingival recession, i.e. the position of the gin-
gival margin with respect to the cement enamel 
junction (CEJ); 
•  CAL (clinical attachment level): i.e. the position of 
the attachment in relationship to the CEJ; 
•  IBPD (intrabony pocket depth): distance between 
the CEJ and the bone crest. 
Periodontal pockets were measured with a 
manual probe marked in millimiter increments. 
Bleeding on probing was recorded and the presence 
of plaque was registred mesially, buccally, distally, 
and lingually. Data were obtained at baseline before 
treatment and at 10 days, and 6,9, and 24 months after 
treatment. 
Surgical Technique 
After local anaesthesia, intrasulcular incisions 
were made at the buccal and lingual sides with 
Bard-Parker surgical blade n° 15, at least one tooth 
away from the mesial portion, distally to the graft site, 
to create access for the tools and facilitate the direct 
clinical view of the defect [fig. 3-4]. 
A full-thickness flap was elevated and the 
granulation tissue was removed showing the true 
extension and depth of the infra-bone defect. 
Debridement and root preparation were carried 
out with hand and ultrasonic instruments [fig. 5]. 
Subsequently, the graft material was prepared 
and positioned: 0.5 cc of autologous bone from in-
tra-oral donor sites blended with two bundles of EHA 
fibres (Biopolimero Hyaloss® Matrix) and a few 
drops of physiological solution [fig. 6]. 
Excess fluids were removed with a sterile gauze 
and the graft material was locally administered. 
Finally, the flap was re-positioned and sutured 
with single stitches. Firm pressure was exerted with 
fingers for 2 - 3 minutes using a gauze dipped in 
physiological solution, to reduce the blood clot and 
promote healing [fig. 7-8]. 
After surgery, patients were instructed to rinse 
their mouths twice daily with 10 ml of 0.2 % 
chlorexidine for 6 weeks. 
 
RESULTS 
The management of the soft tissues was easy and 
healing almost in a high rate occurred after the first treat-Int. J. Med. Sci. 2009, 6 
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ment. During sutures removal, no important tissues 
inflammations were observed. At a 10-day follow-up, 
post-operative clinical assessment demonstrated a 
gingivitis grade of 0 or 1. Thanks to the bacteriostatic 
properties of the tested polymer, a more effective 
control of the surgical wound no bacterial contamina-
tion of the surgical site was observable in all instances 
[fig. 9]. Post-operative radiographs showed absence of 
bone remodelling, and satisfactory filling of the in-
fra-bone defects with the graft material in situ. After 6 
months, radiographs showed presence of mild bone 
remodelling and excellent infra-bone filling [fig. 
10-11]. 
At 9 months from the procedure the dental ele-
ments were virtually stables, with a mean gCAL (gain 
hi clinical attachment) of 2.6mm; radiographic 
evaluation showed defect filling and good prognosis 
[fig. 12-13]. 
After 24 months clinical [fig. 14] and radio-
graphic [fig. 15] re-evaluation shows a present and 
satisfactory filling [Tables 1 and 2].   
DISCUSSION  
Through its complex interactions with matrix 
components and cells, HA has multifaceted roles in 
biology utilizing both its physicochemical and bio-
logical properties. 
HA has a primary role in the principal biological 
processes such as cell organization and differentia-
tion.  
It is postulated that the morphogenetic effects of 
HA are due to its ability to act as a template for as-
sembly of a multi-component, pericellular matrix as 
well as to its physical properties [1,4]. This matrix 
would provide a hydrated environment in which cells 
are separated from structural barriers to morphoge-
netic changes and receive signals from HA itself and 
from associated factors [4,12]. 
HA is an essential component of extracellular 
matrix. It interacts with other macromolecules and 
plays a predominant role in tissue morphogenesis, 
cell migration, differentiation, and adhesion [4,12, 13]. 
Recent in vitro studies have suggested potential 
roles for these two molecules in various aspects of 
endothelial function It appears to exert its biological 
effects through binding interactions with at least two 
cell surface receptors: CD44 and receptor for 
HA-mediated motility (RHAMM) [14-16].  
Interactions between basal epithelial cells and 
the extracellular matrix are mediated by special re-
ceptors on the cell surface which are known as in-
tegrins and belong to the family of cellular adhesion 
molecules (CAM) [17]. Several studies suggest that 
integrin-mediated interaction plays a decisive role in 
the regulation of proliferation, migration, and differ-
entiation of the epithelial cells [2,12,18,19]. Following 
the surgical treatment of adult periodontitis, the 
epithelial regeneration of the periodontal attachment 
is non-physiological and thus unsatisfactory, if mem-
branes or artificial bone material are not used. 
Re-epithelialization is based on the proliferation, mi-
gration, and differentiation of basal epithelial cells 
which are in contact with a wound matrix and whose 
molecular makeup differs from the extracellular ma-
trix of intact regions [17]. 
The general physicochemical and biological 
properties of HA, are utilized in the various processes 
of wound healing: inflammation, granulation and 
re-epithelization [17,20,21]. Inflammation occurs 
when the entire organism reacts to pathogenic agents 
penetration inside a wound, and all the possible de-
fence systems are activated [15,16,22]. When wound 
becomes inflamed several factors necessary to the sub-
sequent healing phases are generated such as growth 
factors and cytokines, which promote migration of in-
flammatory cells, fibroblasts and endothelial cells into 
the damaged site. It has been showed that fibroblasts 
cultured in presence of increasing doses of HA have 
an increased production of pro-inflammatory cyto-
kines such as TSG-6, TNF-α, IL-Iβ and IL-δ, triggered 
by CD44 receptors [12,15-17,21,22].  
It has been shown that high molecular weight 
HA is an angiogenesis inhibitor, while low molecular 
weight HA oligosaccharides had a marked angiogenic 
effect in a series of experimental models, as well as 
stimulating the production of collagen in endothelial 
cells [23]. 
Thanks to its hygroscopic, rheological and vis-
coelastic properties, HA can influence the cell func-
tion that modify the surrounding micro and macro 
environment as a result of complex interactions with 
the cells and other extracellular matrix components 
[6]. 
This characteristic is largely responsible for the 
consistency of the active component that can act as a 
barrier to the spread of any bacteria penetrating the 
tissues including those of the periodontium. It is 
conceivable that hyaluronan administration to perio-
dontal sites could achieve comparable benefits in 
periodontal healing and surgery, hence aiding treat-
ment of periodontal disease [24,25]. 
HA can be an ideal vector for the bone morpho-
genic proteins (BMP), the only growth factors uni-
versally recognized to be able to stimulate the forma-
t i o n  o f  n e w  b o n e  t i s s u e  [ 2 6 - 2 9 ] .  H A  o f  a p p r o p r i a t e  
molecular weight alone in optimal concentration in-
duce osteoblast differentiation and bone formation Int. J. Med. Sci. 2009, 6 
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[8]. In fact HA has a molecular weight-specific and 
dose-specific mode of action that may enhance the 
osteogenic and osteoinductive properties of bone 
graft materials and substitutes due to its stimulatory 
effects on osteoblasts [30]. Considering that no pre-
vious report exist reporting on the use of EHA com-
bined with autologous bone but without the applica-
tion of a membrane in the treatment of infra bone de-
fects, our clinical results are encouraging considering 
that in a similar study a mean value of the increase of 
the bone height of 0.5 mm was obtain with membrane 
application [31]. 
 
CONCLUSIONS 
All these properties make HA useful in perio-
dontal regenerative therapy as a coadjuvant of 
autologous bone grafting. In contact with the patient's 
blood or saline solution, the Hyaloss® matrix forms a 
gel almost instantly, thus facilitating the application 
of the bone fragments. 
The Hyaloss® matrix is highly multipurpose, 
because at room temperature it can form a biode-
gradable, biocompatible gel that can be adapted from 
the operator to the desired consistency, by regulating 
the blood and saline volume. 
In fact, the Hyaloss® matrix has a dual function: 
on one hand its physiochemical properties facilitate 
the application of bone graft in the damaged site and 
on the other hand, it creates an environment with a 
rich content of HA, with all the advantages deriving 
from the phenomenon. 
The present study’s clinic and radiologic results 
showed positive bone formation without a signiﬁcant 
inﬂammatory host response. We feel that using 
autologous bone and EHA is appropriate for per-
forming clinical infra osseous defects. 
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Tables and Figures 
Table 1: Medium gain obtained durig Surgical treatment with Hyaloss
® matrix. 
Patient Age Sex FMPS FMBS Osseous  defect  Surgical site PPD (initial)  PPD (final)  Cal  Medium gain 
1  44 F 100 100 Defect  combined   
1 and 2 walls 
32  -  33  7,8 -  5,5 3,5 -  2,9 6,4 -  6,8 4,3  -  2,6 
2  40  M  50  50  Defect at 3 walls  35 - 36  7,5  -  5,0  4,3  -  3,8  6  -  6,4  3,3 - 1,3 
3  40  M  50  50  Defect at 3 walls  44 - 45  7,5  -  5,0  4,3  -  3,1  4  -  4,3  3,3 - 1,9 
4 28  M  60  100  Defect  combined 
 1 and 3 walls 
41  -  42  5,8 -  3,5 2,8 -  2,0 5,8 -  6  3  -  1,5 
5  34 F 100 100 Defect  combined 
 1 and 2 walls 
11  -  21  7,8 -  7,4 3,3 -  3,0 4,3 -  4  4,5  -  4,4 
6 36  F  60  40  Defect  combined 
 1 and 3 walls 
15 - 16  5,0  -  4,5  2,8  -  2,8  5  -  7  2,3 - 1,8 
7 44  F  50  20  Defect  combined 
 1,2 and 3 walls 
45  -  46  5,0 -  7,8 3,1 -  3,9 3,8 -  5,1 1,9  -  3,9 
8 52  M  60  60  Defect  combined 
 2 and 3 walls 
11  -  12  5,8 -  4,8 2,0 -  2,0 4,5 -  4  3,8  -  2,8 
9 60  F  80  80  Defect  combined 
 1 and 2 walls 
42  -  43  3,5 -  5,8 2,5 -  2,8 2,3 -  4,4 1  -  3 
 
Table 2: Graphical represen-
tation of Medium gain per pa-
tient for each surgical site ob-
tained durig treatment with 
Hyaloss
® matrix.  
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Fig. 1: Pre-operative periapical radiography 
 
Fig. 2: Initial probing 
 
Fig. 3: Surgical flap 
 
Fig. 4: Flap elevation, intra-surgical  evaluation of the 
parameters and surgical curettage of the intra-osseous 
defect 
 
Fig. 5: Autogenous bone graft harvested by a mini-bone 
scraper (Safescraper curve or Micross) 
 
Fig. 6: Autogenous bone graft mixed with Hyaloss® matrix 
   
Fig. 7: Flap replacement and nylon 4-0 single stitches su-
tures. 
 
Fig. 8: Flap replacement and nylon 4-0 single stitches su-
tures. 
 
Fig. 9: Clinical re-evaluation 10 days after surgery 
 
Fig. 10: Clinical re-evaluation 6 months after surgery 
 
Fig 11: Radiographic re-evaluation 6 months from surgery 
 
 
Fig. 12: Clinical re-evaluation 9 months after surgery Int. J. Med. Sci. 2009, 6 
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Fig. 13: Radiographic follow up at 9 months after surgery 
 
 
Fig.14: Clinical re-evaluation 24 months after surgery 
 
 
Fig. 15: Radiographic follow up at 24 months after surgery 
 